SPARC Q2 net loss widens to Rs83.49cr on higher clinical trial costs
Sun Pharma Advanced Research (SPARC) reported 2.62% growth in the Sep-20 quarter top line revenues at Rs17.64cr on a consolidated basis.
Nov 09, 2020 05:11 IST India Infoline News Service
Sun Pharma Advanced Research (SPARC) reported 2.62% growth in the Sep-20 quarter top line revenues at Rs17.64cr on a consolidated basis. SPARC is in the sole business of clinical trials and research and that being a long gestation investment requires substantial upfront losses to be taken. While the company is trying to raise funds in the market to meet the funding gap, it is temporarily being supported by its parent company, Sun Pharma.
While the pharma and API business have benefited from the COVID pandemic, the research business has not gained significantly.
Financial highlights for Sep-20 compared yoy and sequentially
| Sun Pharma Advanced Research | |||||
| Rs in Crore | Sep-20 | Sep-19 | YOY | Jun-20 | QOQ |
| Revenues | 17.64 | 17.19 | 2.62% | 185.45 | -90.49% |
| Profit After Tax (PAT) | -83.49 | -63.16 | Not Relevant | 56.69 | Not Relevant |
| Diluted EPS (Rs) | ₹ -3.19 | ₹ -2.41 | ₹ 2.16 | ||
| PAT Margins | -473.30% | -367.42% | 30.57% | ||
